Scanning through a comparison of FMG & RIO:
- Both have the same 50/50 split of NAV and EV/EBITDA methodology, although a slightly higher discount rate for FMG (9.8% vs 9.2%).
- FMG's NAV is $12.23, well below the current share price whereas RIO's is $132.9 which is a significant difference.
- FMG and RIO have different financial years so the IO price assumptions differ, I presume in the background the same prices are used, it's just which financial year the respective price forecasts fall into that causes the difference.
- FMG's production is expected to increase about 10% over the next 4 years compared to 8.7% for RIO so a bit of a valuation benefit to FMG there.
- FMG's cash costs are expected to increase by 33% over the next 4 years whereas RIO's costs are expected to increase just 9.6% so this is a major difference.
- All other divisional EBITDA returns are mostly expected to increase for RIO over the next 4 years.
- FMG's EPS are expected to decline by -83% compared to -60% for RIO, that's a major difference.
Key takeaways for me when comparing FMG to RIO is RIO has more reliable valuation support due to:
- Cost control which means IO earnings don't drop off as quickly relative to now; and
- RIO obtains significant valuation support from its other divisions leading to a significantly higher NAV.
- FMG's valuation support primarily comes from the EV/EBITDA x4 meaning FMG's valuation is heavily reliant on currently unannounced exploration and other growth factors to be generated from current earnings.
Basically, Goldman's is saying throughout the cycle, RIO has more tangible valuation drives than FMG whereas FMG is more speculative.
RIO.pdf
FMG.pdf
BHP.pdf
- Forums
- ASX - By Stock
- FMG
- Iron ore price
Iron ore price, page-35217
-
- There are more pages in this discussion • 17,769 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FMG (ASX) to my watchlist
(20min delay)
|
|||||
Last
$22.50 |
Change
0.395(1.79%) |
Mkt cap ! $69.53B |
Open | High | Low | Value | Volume |
$22.41 | $22.64 | $22.22 | $69.62M | 3.095M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 4742 | $22.49 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$22.50 | 8263 | 39 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
21 | 10698 | 22.500 |
12 | 5444 | 22.490 |
9 | 5818 | 22.480 |
12 | 5198 | 22.470 |
12 | 8290 | 22.460 |
Price($) | Vol. | No. |
---|---|---|
22.510 | 4304 | 27 |
22.520 | 11307 | 39 |
22.530 | 11376 | 19 |
22.540 | 6467 | 9 |
22.550 | 4048 | 7 |
Last trade - 15.56pm 15/07/2024 (20 minute delay) ? |
Featured News
FMG (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online